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Introduction: We investigated the effects of intravenous and intratracheal administration of salbutamol on lung
morphology and function, expression of ion channels, aquaporin, and markers of inflammation, apoptosis, and
alveolar epithelial/endothelial cell damage in experimental pulmonary (p) and extrapulmonary (exp) mild acute
respiratory distress syndrome (ARDS).
Methods: In this prospective randomized controlled experimental study, 56 male Wistar rats were randomly assigned
to mild ARDS induced by either intratracheal (n = 28, ARDSp) or intraperitoneal (n = 28, ARDSexp) administration of
E. coli lipopolysaccharide. Four animals with no lung injury served as controls (NI). After 24 hours, animals were
anesthetized, mechanically ventilated in pressure-controlled mode with low tidal volume (6 mL/kg), and randomly
assigned to receive salbutamol (SALB) or saline 0.9% (CTRL), intravenously (i.v., 10 μg/kg/h) or intratracheally (bolus,
25 μg). Salbutamol doses were targeted at an increase of ≈ 20% in heart rate. Hemodynamics, lung mechanics, and
arterial blood gases were measured before and after (at 30 and 60 min) salbutamol administration. At the end of the
experiment, lungs were extracted for analysis of lung histology and molecular biology analysis. Values are expressed as
mean ± standard deviation, and fold changes relative to NI, CTRL vs. SALB.
Results: The gene expression of ion channels and aquaporin was increased in mild ARDSp, but not ARDSexp. In
ARDSp, intravenous salbutamol resulted in higher gene expression of alveolar epithelial sodium channel (0.20 ± 0.07 vs.
0.68 ± 0.24, p < 0.001), aquaporin-1 (0.44 ± 0.09 vs. 0.96 ± 0.12, p < 0.001) aquaporin-3 (0.31 ± 0.12 vs. 0.93 ± 0.20, p <
0.001), and Na-K-ATPase-α (0.39 ± 0.08 vs. 0.92 ± 0.12, p < 0.001), whereas intratracheal salbutamol increased the gene
expression of aquaporin-1 (0.46 ± 0.11 vs. 0.92 ± 0.06, p < 0.001) and Na-K-ATPase-α (0.32 ± 0.07 vs. 0.58 ± 0.15, p < 0.001).
In ARDSexp, the gene expression of ion channels and aquaporin was not influenced by salbutamol. Morphological and
functional variables and edema formation were not affected by salbutamol in any of the ARDS groups, regardless of
the route of administration.
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Conclusion: Salbutamol administration increased the expression of alveolar epithelial ion channels and aquaporin in
mild ARDSp, but not ARDSexp, with no effects on lung morphology and function or edema formation. These results
may contribute to explain the negative effects of β2-agonists on clinical outcome in ARDS.
Keywords: Salbutamol, Acute respiratory distress syndrome, Elastance, Alveolar epithelial cells, Epithelial sodium
channel, EdemaIntroduction
Acute respiratory distress syndrome (ARDS) is character-
ized by an increased permeability of the alveolar-capillary
membrane [1]. In addition, fluid clearance is reduced,
resulting in congestion, atelectasis and alveolar edema,
which can impair gas exchange and respiratory mechanics
[2], and even increase mortality [3]. Lung fluid homeosta-
sis is controlled by different mechanisms [4]. The removal
of alveolar edema depends on the transport of salt and water
across the alveolar epithelial sodium channels (ENaC),
followed by extrusion of fluid into the lung interstitium via
basolaterally located Na-K-ATPase. The resulting gradient
in Na+ concentration absorbs water from the airspace by a
transcellular route via aquaporins (AQP). Moreover, in-
creased apoptosis and necrosis of alveolar epithelial cells re-
sult in a loss of barrier and transport properties [5].
The potential of β2-adrenoreceptor agonists to reduce
alveolar-capillary permeability and increase fluid clearance
has been investigated [6-8]. These drugs upregulate apical
Na+ and Cl− channels in alveolar type II cells, reduce neu-
trophil influx into the lungs, and inhibit inflammatory cy-
tokines [9-11]. Different experimental studies have shown
that nebulized salbutamol reduces lung edema [12,13]. In
a single-center phase II trial [14], intravenous β2-agonist
administration decreased lung edema in ARDS patients.
However, in multicenter randomized controlled trials,
intravenous [15] or nebulized [16] administration of β2-
agonists increased mortality or failed to show beneficial
effects, respectively, in ARDS patients. Nevertheless,
those studies [14-16] included patients with ARDS of
different etiologies and used different routes of adminis-
tration, which could have affected the results. Yet, to
our knowledge, these factors have not been systematic-
ally addressed. Since in pulmonary (p) ARDS the pri-
mary damage occurs in alveolar epithelial cells [17-19],
the effects of salbutamol on ion channel gene expres-
sion would be more pronounced. In contrast, in extra-
pulmonary (exp) ARDS, the primary damage occurs in
endothelial cells and in this case salbutamol would be
expected to have less effect on ion channel gene expres-
sion regardless of the route of administration.
The aim of this study was to investigate the effects of
salbutamol administered intravenously (i.v.) and intratra-
cheally (i.t.) in mechanically ventilated rats with mildARDSp and ARDSexp on: 1) lung function and histology,
and 2) biological markers associated with alveolar fluid
clearance, inflammation, apoptosis, and damage inflicted
on alveolar epithelial and endothelial cells.Material and methods
This study was approved by the Ethics Committee of the
Carlos Chagas Filho Institute of Biophysics, Health Sciences
Centre, Federal University of Rio de Janeiro, Brazil. All
animals received humane care in compliance with the
“Principles of Laboratory Animal Care” formulated by the
National Society for Medical Research and the “Guide for
the Care and Use of Laboratory Animals” prepared by the
National Academy of Sciences, USA.Induction of ARDS and anesthesia
Sixty adult male Wistar rats (242–336 g) were used.
ARDSp (n = 28) was induced by intratracheal injection
of E. coli lipopolysaccharide (LPS, serotype 055:B5;
Sigma Aldrich, São Paulo, SP, Brazil) (200 μg suspended
in 100 μL saline 0.9%), and ARDSexp (n = 28) by intra-
peritoneal injection of LPS (1000 μg suspended in
1000 μL saline 0.9%). For this purpose, rats were anes-
thetized with sevoflurane (2.5 vol.%; Cristália, São
Paulo, SP, Brazil). After recovering from anesthesia, all
rats were kept under observation in cages. These doses
of LPS were chosen because they can yield a 1.5-fold-in-
crease in static lung elastance in both ARDSp and ARD-
Sexp, according to a previous study of our group [18].
Four rats, which did not receive LPS or mechanical ven-
tilation, served as non-injured controls for molecular
biology analysis.
Twenty-four hours after ARDS induction, rats were
premedicated intraperitoneally (i.p.) with 1–2 mg/kg
midazolam (Dormicum; União Química, São Paulo, SP,
Brazil) and 50–100 mg/kg ketamine (Vetanarcol; König
Laboratories Brazil, Santana de Parnalha, SP, Brazil). An
intravenous catheter (Jelco 24G) was inserted into the
tail vein for continuous infusion of 2 mg/kg/h midazo-
lam, 100 mg/kg/h ketamine, and 7 mL/kg/h Ringer’s
lactate (B. Braun, Crissier, Switzerland). Animals were
kept in the supine position throughout the experiment.
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Animals were tracheotomized and a polyethylene catheter
(PE-50) was introduced into the right internal carotid artery
for blood sampling and mean arterial blood pressure
(MAP) measurement. Electrocardiogram (ECG), MAP and
rectal temperature were continuously recorded (Networked
Multiparameter Veterinary Monitor LifeWindow 6000 V,
Digicare Animal Health, Florida, USA). Body temperature
was maintained at 38.5°C ± 1°C using a heating pad
(Insight Ltda, São Paulo, SP, Brazil). The left jugular vein
was cannulated (Jelco® 24G catheter, Johnson & Johnson,
São José dos Campos, Brazil) for infusion of salbutamol or
Ringer’s lactate.Measurements and experimental protocol
After the end of preparation, arterial blood gases
(iSTAT System, CG8+ cartridge; Abbott Point of Care
Inc., Princeton, NJ, USA) and hemodynamics were mea-
sured (Baseline 1 – BL1). Animals were paralyzed (pancur-
onium bromide, 2 mg/kg i.v.) and mechanically ventilated
(Servo-i, MAQUET, Solna, Sweden) in pressure-controlled
mode with tidal volume (VT) = 6 mL/kg, respiratory
rate (RR) = 80 breaths/min, inspiratory-to-expiratory
ratio (I:E) = 1:2, fraction of inspired oxygen (FIO2) =
0.4, and positive end-expiratory pressure (PEEP) = 3
cmH2O. Gelafundin® (B. Braun, Melsungen, Germany)
was administered (in steps of 0.5 mL) to maintain
MAP >60 mmHg. After 5 min of stabilization, respiratory
system mechanics, arterial blood gases and hemodynamics
were measured (Baseline 2 – BL2).
In both ARDSp and ARDSexp groups, rats were then
randomly assigned to one of four subgroups (n = 7/sub-
group) to receive i) intravenous salbutamol (SALB-i.v.,
10 μg/kg/hour for 30 min) (Hipolabor, Sabará, MG, Brazil),
ii) intravenous saline 0.9% (CTRL-i.v., 3 mL for 30 min), iii)
intratracheal salbutamol (SALB-i.t., 25 μg suspended in
50 μL), or iv) intratracheal saline 0.9% (CTRL-i.t., 50 μL).
Intratracheal applications were performed using a high
pressure syringe (Model FMJ-250; Penn-Century, Inc.,
Wyndmoor, PA, USA) connected to an aerosolizer de-
vice (Microsprayer Model IA-1C; Penn-Century, Inc.,
Wyndmoor, PA, USA). Intratracheal β2-agonist doses
were chosen based on a previous report [12] and pilot
experiments showing hemodynamic instability when
heart rate (HR) increased more than 20%. Intravenous
doses were selected based on pilot experiments to
achieve an increase of ≈ 20% in HR. After 1-hour mech-
anical ventilation, a laparotomy was performed and hep-
arin (1000 IU; Hipolabor, Sabará, MG, Brazil) was
injected i.v.. Animals were then killed with thiopental
(25 mg i.v.; Cristália, São Paulo, SP, Brazil), and their
lungs extracted for histological and molecular biology
analysis (Figure 1).Hemodynamics
HR and MAP were measured at BL1 and BL2, and also at
5 min (T5), 30 min (T30) and 60 min (T60) during the ex-
perimental period. T5 measurements were performed to
assess the immediate hemodynamic effects of salbutamol.
Blood gases and respiratory system mechanics
Arterial blood gases were measured at BL1, BL2, T30, and
T60. Airway pressure (Paw) and airflow were measured
with a differential pressure transducer (UT-PDP-300;
SCIREQ, Montreal, Quebec, Canada) and continuously re-
corded. All signals were filtered (100 Hz), amplified in a 4-
channel signal conditioner (SC-24; SCIREQ, Montreal,
Quebec, Canada), and sampled at 200 Hz with a 12-bit
analogue-to-digital converter (NI-DAQmx 8.7.1, Austin,
Texas, USA). Peak (Pawpeak) and mean (Pawmean) airway
pressures were computed. The elastance (Ers) and resist-
ance (Rrs) of the respiratory system were calculated using
the equation of motion. Respiratory variables were com-
puted from continuous recordings of airflow and Paw at
BL2, T30, and T60 using routines written in MATLAB
(version 7.14; The Mathworks Inc., Natick, MA, USA).
Postmortem processing
For postmortem processing, the trachea was clamped at
end-expiration at PEEP of 3 cmH2O.
Wet-to-dry ratio
The wet-to-dry (W/D) ratio was determined in the right
middle lobe as described elsewhere [20]. Briefly, the right
middle lobe was removed, weighted (wet weight), and then
dried in a microwave oven at low power (200 W) for
5 min. The drying process was repeated until the differ-
ence between two consecutive lung weight measurements
was less than 0.002 g. The last weight recorded repre-
sented the dry weight.
Histology
The right lower lung lobe was fixed in 4% buffered formal-
dehyde, embedded in paraffin, cut into slices of 3 μm thick-
ness, and stained with hematoxylin-eosin for histological
analysis. Photomicrographs at magnifications of ×25, ×100
and ×400 were obtained from eight non-overlapping fields
of view per section using a light microscope. Diffuse alveo-
lar damage (DAD) was quantified using a weighted scoring
system, as described elsewhere [21]. Briefly, values from
0 to 4 were used to represent the severity of edema,
hemorrhage, inflammatory infiltration, and overdistension,
with 0 standing for no effect and 4 for maximum severity.
Additionally, the extent of each score characteristic per
field of view was determined by using values of 0 to 4,
with 0 standing for no appearance and 4 for complete in-
volvement. Scores were calculated as the product of sever-
ity and extent of each feature, in the range of 0 to 64.
Figure 1 Timeline representation of the experimental protocol. ARDS = acute respiratory distress syndrome; T5, T30, and T60 =measurement
points at 5, 30, and 60 min after initiation of intervention; PCV = pressure-controlled ventilation.
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Biological markers of inflammation, alveolar epithelial and
endothelial cell injury, apoptosis, and alveolar fluid clearance
Quantitative real-time reverse transcription polymerase
chain reaction (PCR) was performed to measure the mRNA
expression of biological markers associated with inflamma-
tion [interleukin (IL)-6, macrophage inflammatory protein
(MIP)-2, and tumor necrosis factor (TNF)-α], apoptosis
[pro-caspase-3, BH3 interacting-domain death agonist
(Bid), and Bcl-2-associated X protein (Bax)], alveolar epi-
thelial type I cell damage [receptor for advanced glycation
end-products (RAGE)], endothelial cell injury [vascular cell
adhesion molecule (VCAM)-1], and alveolar fluid clearance
[ENaC-α, Na-K-ATPase (α subunit), and AQP-1 and −3].
Central slices of the left lung were cut, collected in cryo-
tubes, quick-frozen by immersion in liquid nitrogen, and
stored at −80°C. Total RNA was extracted using the SV
Total RNA Isolation System (Promega, Fitchburg, WI,
USA). RNA concentration was measured by spectropho-
tometry in Nanodrop® ND-1000. First-strand cDNA was
synthesized from total RNA using M-MLV Reverse Tran-
scriptase Kit (Invitrogen, Carlsbad, CA, USA). The primers
and Real-Time PCR protocols are described in detail in the
Additional file 1.
Statistical analysis
Values are expressed as mean ± standard deviation (SD) un-
less otherwise specified. Differences between groups at BL1
and BL2, as well as in gene expression, were tested using
one-way ANOVA with Bonferroni correction. Between-
and within-groups differences (T5, T30, T60; time, group,
and time × group effects) were tested with two-way
ANOVA and adjusted for repeated measures according to
the Bonferroni method. A mixed linear model followed by
Tukey-Kramer test was used to analyze the histologicalfeatures of the DAD score. All data were tested separately
for ARDSp and ARDSexp groups. All statistical analyses
were performed using SPSS (version 20; SPSS Inc., Chicago,
IL, USA), GraphPad Prism (version 5.01; GraphPad Soft-
ware, La Jolla, CA, USA) and the mixed procedure of SAS
(version 9.2; SAS Institute, Cary, NC, USA). Statistical sig-
nificance was accepted at α = 0.05.
Results
The groups did not differ in body weight, dose of
anesthesia, amount of crystalloids, and fluid therapy
(Additional file 2: Table S2).
In both ARDSp and ARDSexp, doses of salbutamol were
1.5 ± 0.1 μg/kg/h (i.v.) and 25 ± 0 μg/kg/h (i.t.), leading to
an increase in HR with a progressive decrease in MAP, as
compared to BL2, regardless of the route of drug adminis-
tration (Figure 2).
Pawpeak, Ers and Rrs increased over time with the admin-
istration of saline or salbutamol in both ARDS groups, re-
gardless of the route of administration (Additional file 2:
Table S3).
Intravenous injection of salbutamol increased the ex-
pression of ENaC-α, AQP-1, AQP-3 and Na-K-ATPase-α
in ARDSp, but not in ARDSexp (Figure 3). Intratracheal
salbutamol increased the gene expression of AQP-1 and
Na-K-ATPase-α in ARDSp. In addition, in ARDSp, the
intravenous injection of salbutamol induced higher gene
expression of AQP-3 and Na-K-ATPase-α than intratra-
cheal instillation of salbutamol.
In both salbutamol groups, partial pressure of arterial
carbon dioxide (PaCO2) and arterial pH (pHa) deterio-
rated over time, irrespective of the etiology of lung injury,
while arterial oxygen partial pressure (PaO2) showed a
greater decrease in ARDSp (Table 1).
The W/D ratio and DAD score were not affected by
salbutamol in any of the ARDS groups, regardless of the
route of administration (Additional file 2: Figure S1 and
Figure 2 Heart rate (HR) and mean arterial pressure (MAP) during the experimental protocol. All values are expressed as mean and
standard deviation. Effects of initiation of mechanical ventilation were tested with a paired t-test. Differences between and within groups
(group and time effects, T5, T30, T60 as well as their interactions) were tested separately for ARDSp and ARDSexp using two-way ANOVA and
adjusted for repeated measures according to the Bonferroni method. SALB = salbutamol; CTRL = control; i.t. = intratracheally; i.v. = intraven-
ously; BL1 = baseline 1; BL2 = baseline 2; T5, T30, and T60 = 5, 30, and 60 min after initiation of therapy; ARDSp = pulmonary acute respiratory
distress syndrome; ARDSexp = extrapulmonary acute respiratory distress syndrome; ns = non-significant; * = p < 0.05 vs. CTRL; ** = p < 0.01 vs.
CTRL; *** = p < 0.001 vs. CTRL; # = p < 0.05 vs. SALB; ### = p < 0.001 vs. SALB.
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expression of markers of inflammation, apoptosis, and
endothelial and epithelial damage was not affected by
intratracheal or intravenous administration of salbuta-
mol in any of the ARDS groups.Discussion
The main findings of this study were that: 1) the gene
expression of ENaC-α, AQP-1, AQP-3, and Na-K-ATPase-
α was reduced in mild ARDSp, but not ARDSexp, 2) in
mild ARDSp, intravenous salbutamol increased the gene
Figure 3 Gene expression of channels associated with alveolar fluid clearance and pulmonary edema formation. ENaC-α = alpha subunit
of the epithelial sodium channel; Na-K-ATPase-α = alpha subunit of the Na-K-ATPase; AQP-1 = aquaporin 1; AQP-3 = aquaporin 3. Differences
between groups (SALB vs. CTRL; SALB-iv vs. SALB-it) were tested separately for ARDSp and ARDSexp using one-way ANOVA followed by Bonferroni
correction. Statistical significance was accepted at α = 0.05. All values are expressed as mean and standard deviation. ** = p < 0.01; *** = p < 0.001 vs.
CTRL; # = p < 0.05; ## = p < 0.01 vs. SALB-i.t.; NI = non-injured controls; CTRL = control; SALB = salbutamol; i.t. = intratracheally; i.v. = intravenously;
ARDSp = pulmonary acute respiratory distress syndrome; ARDSexp = extrapulmonary acute respiratory distress syndrome.
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α, while intratracheal salbutamol increased the gene expres-
sion of AQP-1 and Na-K-ATPase-α, 3) in mild ARDSexp,
the gene expression of ion channels and AQP was not
influenced by salbutamol, regardless of the route of admin-
istration, and 4) morphofunctional variables and edema for-
mation were not modulated by salbutamol, regardless of
the ARDS model and route of drug administration.
To our knowledge, this is the first systematic investiga-
tion of the potential beneficial effects of salbutamol, ad-
ministered by the intravenous and intratracheal routes, on
lung morphology and function, inflammation, alveolar epi-
thelial and endothelial cell damage, apoptosis, as well as
on ion channels involved in the resolution of pulmonary
edema in ARDSp and ARDSexp. In both models, the same
agent, LPS, was used to induce ARDS. LPS challenges typ-
ically result in considerable tissue injury, characterized byneutrophil accumulation in the alveolar and interstitial
spaces, alveolar wall thickening, and accumulation of pro-
teinaceous edema in the alveolar space, which represent
some of the hallmarks of experimental ARDS [22]. Salbu-
tamol doses administered i.v. or i.t. were titrated based on
HR, which is a clinically measurable target closely related
to plasma drug concentration [23]. Salbutamol was chosen
due to the following reasons: 1) it is a β2-agonist that has
been previously used in clinical investigations of ARDS
[14,15]; 2) it is available for both intravenous and intratra-
cheal administration in the clinical setting; and 3) it can be
easily titrated owing to its relatively short half-life.
It is worth noting that lung injury was associated with
a decrease in the gene expression of ENaC-α, AQP-1,
AQP-3, and Na-K-ATPase-α, as compared to non-injured
animals, in ARDSp, but not in ARDSexp. In mild ARDSp,
salbutamol increased the gene expression of ENaC-α,
Table 1 Arterial blood gases
Variable ARDSp ARDSexp
CTRL-it SALB-it CTRL-iv SALB-iv CTRL-it SALB-it CTRL-iv SALB-iv
PaO2 [mmHg (kPa)]
BL1 236 ± 61 238 ± 66 227 ± 50 200 ± 46 249 ± 36 249 ± 50 241 ± 42 244 ± 51
(31.5 ± 8.0) (31.8 ± 8.8) (30.3 ± 6.6) (26.7 ± 6.1) (33.2 ± 4.9) (33.2 ± 6.6) (32.2 ± 5.6) (32.5 ± 6.8)
BL2 230 ± 88 249 ± 65 238 ± 74 246 ± 69 279 ± 79 292 ± 75 212 ± 62 257 ± 97
(30.7 ± 11.8) (33.2 ± 8.7) (31.7 ± 9.9) (32.8 ± 9.3) (37.2 ± 10.5) (39.0 ± 10.0) (28.2 ± 8.3) (34.1 ± 12.9)
T30 191 ± 50 210 ± 34 175 ± 43 183 ± 57 225 ± 57 226 ± 39 212 ± 55 244 ± 55
(25.5 ± 6.6) (28.0 ± 4.5) (23.4 ± 5.7) (24.4 ± 7.6) (30.0 ± 7.7) (30.1 ± 5.2) (28.3 ± 7.3) (32.6 ± 7.3)
T60 196 ± 84 205 ± 43 215 ± 72 214 ± 84 252 ± 46 222 ± 42 208 ± 27 251 ± 68
(26.1 ± 11.1) (27.2 ± 5.7) (28.7 ± 9.6) (28.5 ± 11.2) (33.6 ± 6.1) (29.5 ± 5.6) (27.6 ± 3.6) (33.5 ± 9.1)
Time effect p < 0.01 ns
Interaction Ns ns
Group effect Ns ns
PaCO2 [mmHg (kPa)]
BL1 34 ± 6 34 ± 5 34 ± 7 36 ± 6 33 ± 6 31 ± 7 31 ± 7 27 ± 4
(4.6 ± 0.7) (4.6 ± 0.7) (4.5 ± 0.9) (4.8 ± 0.8) (4.4 ± 0.8) (4.2 ± 0.9) (4.1 ± 0.9) (3.6 ± 0.6)
BL2 50 ± 7 43 ± 6 45 ± 6 50 ± 11 40 ± 7 42 ± 5 43 ± 9 39 ± 11
(6.7 ± 0.9) (5.7 ± 0.9) (6.0 ± 0.8) (6.7 ± 1.5) (5.3 ± 1.0) (5.6 ± 0.7) (5.8 ± 1.2) (5.2 ± 1.5)
T30 59 ± 13 47 ± 18 55 ± 12 58 ± 12 45 ± 9 56 ± 12 51 ± 11 44 ± 12
(7.8 ± 1.8) (6.3 ± 2.4) (7.4 ± 1.6) (7.8 ± 1.6) (6.0 ± 1.2) (7.5 ± 1.6) (6.9 ± 1.5) (5.8 ± 1.6)
T60 55 ± 16 55 ± 16 55 ± 9 48 ± 13 46 ± 11 55 ± 13 53 ± 8 52 ± 7
(7.4 ± 2.0) (7.3 ± 2.2) (7.3 ± 1.15) (6.4 ± 1.7) (6.2 ± 1.5) (7.3 ± 1.7) (7.0 ± 1.1) (7.0 ± 0.9)
Time effect p < 0.01 p < 0.001
Interaction Ns ns
Group effect Ns ns
pHa
BL1 7.43 ± 0.08 7.44 ± 0.05 7.46 ± 0.06 7.46 ± 0.06 7.43 ± 0.05 7.45 ± 0.05 7.45 ± 0.07 7.46 ± 0.06
BL2 7.30 ± 0.04 7.36 ± 0.06 7.33 ± 0.04 7.30 ± 0.06 7.32 ± 0.04 7.31 ± 0.04 7.32 ± 0.04 7.30 ± 0.06
T30 7.24 ± 0.07 7.29 ± 0.07 7.28 ± 0.08 7.25 ± 0.08 7.24 ± 0.03 7.19 ± 0.09 7.23 ± 0.06 7.25 ± 0.08
T60 7.24 ± 0.10 7.26 ± 0.08 7.28 ± 0.05 7.27 ± 011 7.25 ± 0.04 7.16 ± 0.10 7.20 ± 0.07 7.25 ± 0.07
Time effect p < 0.001 p < 0.001
Interaction Ns ns
Group effect Ns p < 0.01
BE [mmol/L]
BL1 −1 ± 4 −1 ± 2 0 ± 3 2 ± 1 −3 ± 2 −2 ± 3 −4 ± 2 5 ± 1
BL2 −1 ± 2 −3 ± 2 −2 ± 1 −3 ± 1 −6 ± 4 −5 ± 4 −4 ± 4 −5 ± 2
T30 −3 ± 4 −5 ± 4 −1 ± 2 −2 ± 2 −8 ± 4 −6 ± 5 −6 ± 4 −6 ± 3
T60 −4 ± 6 −3 ± 2 −1 ± 3 −5 ± 4 −7 ± 4 −9 ± 6 −7 ± 4 −4 ± 3
Time effect p < 0.05 ns
Interaction Ns ns
Group effect Ns ns
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Table 1 Arterial blood gases (Continued)
HCO3 [mmol/L]
BL1 23.1 ± 2.7 23.6 ± 2.3 24.5 ± 2.3 26.0 ± 1.6 22.0 ± 2.6 22.0 ± 2.9 21.0 ± 2.4 19.5 ± 1.3
BL2 25.3 ± 1.7 23.1 ± 1.5 24.2 ± 0.9 24.3 ± 2.3 20.7 ± 3.6 21.8 ± 3.3 22.6 ± 4.0 21.6 ± 1.7
T30 24.4 ± 3.3 22.2 ± 5.2 26.2 ± 2.0 25.5 ± 2.1 20.0 ± 3.7 22.0 ± 4.5 22.2 ± 3.7 21.9 ± 1.8
T60 23.9 ± 5.3 24.7 ± 2.9 26.0 ± 2.8 21.9 ± 4.0 20.8 ± 4.1 20.2 ± 5.0 24.8 ± 10.8 23.2 ± 2.3
Time effect Ns ns
Interaction Ns ns
Group effect Ns ns
All values are expressed as mean and standard deviation. Differences between and within groups (group and time effects, BL2-T60 as well as their interactions) were
tested with general linear model statistics and adjusted for repeated measures according to the Bonferroni method for ARDSp and ARDSexp separately. Statistical
significance was accepted at α = 0.05 ns = non-significant; CTRL = control; SALB = salbutamol; it = intratracheally; iv = intravenously; ARDSp = pulmonary acute
respiratory distress syndrome; ARDSexp = extrapulmonary acute respiratory distress syndrome; BL1 = baseline 1; BL2 = baseline 2; T30 and T60 = 30 and 60 min
after initiation of therapy; PaO2 = arterial O2 partial pressure; PaCO2 = partial pressure of arterial CO2; pHa = arterial pH; BE = base excess; HCO3 = bicarbonate level.
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intravenous route. Similar results with β2-agonists have
been observed in different experimental studies [24-26].
The activation of such pathways may increase lung edema
clearance, since in ARDSp the lung epithelium is the first
structure to be damaged, with alveolar flooding and areas
of consolidation [27]. However, we could not detect a re-
duction in pulmonary edema in our animals, as suggested
by the measurement of W/D ratio. The gene expression
associated with the mechanisms involved in edema clear-
ance was enhanced, and it has been shown that channels
translocation to membrane may occur within minutes
[28,29] through a non-genomic, cyclic adenosine mono-
phosphate (cAMP)-dependent pathway. On the other
hand, the gene transcription could be mediated via the
cAMP response binding element as demonstrated by the
progression of lung inflammation [30,31]. To our know-
ledge, to date, this mechanism has not been investigated
for fluid channels in the lung. However, these potential
pathways were not translated into functional data of lung
edema, as observed in Additional file 2: Figure S1. Allied
to this, the time for building the respective proteins and
structures was too short (1 hour), precluding the observa-
tion of an effect on edema clearance. Conversely, in mild
ARDSexp, the first structure to be damaged is the endothe-
lium, with subsequent increase in vascular permeability,Table 2 Diffuse alveolar damage (DAD) score
Variable ARDSp
CTRL-it SALB-it CTRL-iv SA
Cumulative (0–64) 11 [8–12] 9 [7–16] 11 [ 8–13] 13
Edema (0–16) 1 [0–3] 1 [0–6] 2 [1–4] 2
Hemorrhage (1–16) 2 [0–6] 2 [1–2] 1 [1–3] 3
Inflammation (0–16) 4 [1–6] 2 [1–3] 2 [1–5] 4
Overdistension (0–16) 4 [3–6] 4 [2–6] 4 [2–6] 4
Values are expressed as median and interquartile range. Statistical analysis was per
comparisons. Statistical significance was accepted at α = 0.05. ns = non-significant; C
ARDSp = pulmonary acute respiratory distress syndrome; ARDSexp = extrapulmonarmicrovascular congestion, and interstitial edema, but with
relative sparing of the intra-alveolar spaces [27].
In ARDSexp, salbutamol did not affect the gene expres-
sion of ion channels and AQP, regardless of the route of ad-
ministration. There are different possible explanations for
the lack of effect of salbutamol on the gene expression
of ion channels and AQP in ARDSexp: 1) the interstitial
edema produces a barrier-like effect, thus hindering the dif-
fusion of the intravenous β2-agonist into the alveolar epi-
thelial layer; 2) impaired delivery of intravenous salbutamol
to areas of microvascular congestion; 3) collapse of small
airways and alveolar units, preventing the intratracheal
drug from reaching the alveolar epithelium; and 4) almost
normal gene expression, without room for improvement.
It has been suggested that β-agonists decrease the re-
lease of pro-inflammatory mediators [32], reduce cell
apoptosis [33], and improve alveolar epithelial and endo-
thelial repair in experimental lung injury [34,35]. Further-
more, it has been shown that β-agonists differentially
affect ENaC channels by promoting the upregulation of
selective and non-selective channels and that the route of
drug delivery influences its effectiveness [36]. In the
current study, the effect of salbutamol depended on the
etiology of acute respiratory distress syndrome but not
on the route of administration. In addition, salbutamol
had no effect on inflammation, apoptosis or epithelial/ARDSexp
LB-iv CTRL-it SALB-it CTRL-iv SALB-iv
[8–20] 8 [5–11] 8 [5–12] 8 [6–13] 9 [5–13] ns
[0–2] 0 [0–1] 1 [0–1] 1 [0–3] 1 [0–4] ns
[1–5] 2 [1–4] 2 [1–4] 1 [1–4] 2 [0–2] ns
[1–6] 2 [1–2] 2 [1–3] 1 [1–2] 1 [1–2] ns
[3–6] 3 [2–4] 4 [2–4] 4 [2–7] 3 [2–6] ns
formed using a mixed linear model with Tukey-Kramer adjustment for multiple
TRL = control; SALB = salbutamol; it = intratracheally; iv = intravenously;
y acute respiratory distress syndrome.
Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 Real-time polymerase chain reaction analysis of biological markers associated with inflammation [interleukin (IL)-6,
macrophage inflammatory protein (MIP)-2, and tumor necrosis factor (TNF)-α], apoptosis [pro-caspase-3, BH3 interacting-domain death
agonist (Bid), and Bcl-2-associated X protein (Bax)], and damage inflicted on alveolar type I epithelial cells [receptor for advanced
glycation end-products (RAGE)] and endothelium [vascular cell adhesion molecule (VCAM)-1]. All values are expressed as mean and
standard deviation. Differences between groups (SALB vs. CTRL; SALB-iv vs. SALB-it) were tested separately for ARDSp and ARDSexp using
one-way ANOVA followed by Bonferroni correction. Statistical significance was accepted at α= 0.05. * = p < 0.05 vs. CTRL; NI = non-injured control;
CTRL = control; SALB = salbutamol; i.t. = intratracheally; i.v. = intravenously; ARDSp = pulmonary acute respiratory distress syndrome; ARDSexp =
extrapulmonary acute respiratory distress syndrome.
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route of drug administration. There are different explana-
tions for this discrepancy. First, it is possible that salbuta-
mol doses required for inhibition of inflammation and
enhancement of alveolar epithelial and endothelial repair
are different from those required for gene regulation of
ion channels and AQP. Second, since β2-agonists seem to
have anti-inflammatory properties mainly in severe dam-
age and inflammation [32], even promoting inflammation
in the absence of pro-inflammatory stimuli [37], our ani-
mals were less likely to benefit from the anti-inflammatory
effects of salbutamol, as they presented a mild form of
acute lung injury. Third, we cannot refrain from men-
tioning that our experimental models of ARDS were less
responsive than expected to the anti-inflammatory ef-
fects of β2-agonists, although such response has been
shown not to be homogeneous across different models
of lung injury [11]. Fourth, we cannot rule out the fact
that anti-inflammatory, anti-apoptotic and alveolar epi-
thelial/endothelial repair effects are time-dependent.
In both ARDS models, gas exchange and respiratory sys-
tem mechanics were not affected by salbutamol, regardless
of the route of administration. Inhaled salbutamol has been
shown to reduce Rrs in patients with ARDS [38,39]. A pos-
sible explanation for the absence of beneficial effects on
pulmonary function is the use of a relatively low PEEP level
(3 cmH2O), which may have not been sufficient to keep
distal airways and/or alveoli open. Thus, a possible benefi-
cial effect of the β2-agonist on airway smooth muscle tone
and gas exchange may have been overwhelmed by the
effects on lung structures obtained with the ventilator set-
tings. This hypothesis is supported by the fact that respira-
tory mechanics, and also oxygenation, worsened in all
groups in a time-dependent manner. Because we did not
assess the individual contributions of different components
of Rrs, we were not able to detect a possible effect on cen-
tral airway resistance, which has been previously described
[38]. It is worth noting that Rrs deteriorated after intratra-
cheal administration of salbutamol in ARDSp. This finding
is possibly related to the fact that the β2-agonist was ad-
ministered as an intratracheal bolus, which may lead to par-
tial mechanical obstruction of the airways. This hypothesis
is supported by the observation that instillation of saline
0.9% i.t. produced a similar increase in Rrs in ARDSp.Possible clinical implications
The present study provides some mechanistic insights into
the lack of positive effects of β2-agonists on clinical out-
come in ARDS. Even though salbutamol upregulated the
gene expression of ion channels and AQP in mild ARDSp,
it did not enhance edema resolution. Furthermore, salbu-
tamol did not upregulate the expression of those genes in
ARDSexp, which showed a nearly normal expression.
Thus, in the absence of positive effects, the side effects of
β2-agonists may stand out.
Limitations
Our study has several limitations. First, the models of mild
ARDSp and ARDSexp used in the current study might not
fully reproduce the complex features of clinical ARDS.
Second, different salbutamol doses may result in different
effects; thus, further studies are warranted to better ad-
dress this issue. Third, mechanical ventilation with low
tidal volumes led to hypercapnic acidosis, possibly inter-
fering with anti-inflammatory effects [40]. Fourth, the 1-
hour observation period was relatively short, precluding
extrapolation of our findings to longer observation pe-
riods. In this context, even though the 1-hour period is
sufficient to produce changes in gene expression, it may
be too short to translate into protein synthesis.
Conclusion
Salbutamol administration increased the expression of al-
veolar epithelial ion channels and AQP in mild ARDSp,
but not ARDSexp, with no effect on lung morphology and
function, inflammatory mediators, or edema formation.
These results may contribute to explain the negative ef-
fects of β2-agonists on clinical outcome in ARDS.
Key messages
 Gene expression of alveolar epithelial ion channels and
aquaporin differed according to the etiology of ARDS.
 In mild ARDSp, both intratracheal and intravenous
salbutamol increased the gene expression of alveolar
epithelial ion channels and aquaporin.
 In mild ARDSexp, the gene expression of alveolar
epithelial ion channels and aquaporin was not
influenced by salbutamol.
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variables or edema formation, regardless of the
ARDS model and route of drug administration.
Additional files
Additional file 1: This file gives detailed information about extended
material and methods used including one table (Table S1 - Polymerase
chain reaction (PCR) primers used in the study).
Additional file 2: This file contains additional results covering two
tables (Table S2 - Body weight, anesthesia and fluid therapy and
Table S3 - Ventilator parameters and respiratory mechanics) and
one figure (Figure S1 - Wet-to-dry (W/D) ratio).
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